Pfizer Inc.

- Pfizer is focused on deleveraging as quickly as possible and has already repaid $4.4 billion in debt year-to-date. - The company continues to evaluate all options, including potential business development, asset monetization, and strategic capital deployment. - No specific new fundraising through debt or equity was announced during the call. - Pfizer remains open to monetizing assets to support deleveraging and strategic initiatives but has not disclosed any immediate plans for new fundraising. - The company is committed to maintaining financial flexibility and balancing debt reduction with investment in growth and pipeline development.

- Pfizer is open to business development (BD) opportunities, continuously evaluating strategic options related to current assets and potential monetization to support deleveraging and growth. - The company has made significant investments in Seagen and BioNTech, with Seagen integration progressing well and multiple promising oncology programs advancing, indicating continued investment in oncology R&D and commercialization. - Development of new vaccine platforms such as the fourth and fifth generation pneumococcal conjugate vaccines with advanced technology improvements suggests ongoing capital investment in vaccine R&D. - Pfizer is advancing oral obesity-related assets (e.g., oral GIP antagonist and Danuglipron modified release), reflecting strategic investments in innovative oral therapies within metabolic disease. - Focus on building mRNA infrastructure globally with BioNTech collaboration indicates strategic capital deployment to expand cutting-edge vaccine technology capabilities. - The company is prioritizing operational efficiency and cost discipline to optimize capital allocation while supporting pipeline advancement and commercial execution.

- Pfizer expects strong growth from the remaining parts of its business outside COVID, with new products performing better than anticipated this quarter. - In the international market, growth continues robustly, with total patients on treatment increasing and reimbursement expanding in 45 countries. - Vinda shows very strong U.S. growth this year driven by increased diagnosis and new patient starts, though volume growth is expected to slow in 2025 due to new competitive entrants. - ABRYSVO (RSV vaccine) shows momentum with increased market share and uptake in both adult and pediatric segments; expansions in reimbursement and market access ongoing internationally. - Oral obesity treatments like Danuglipron and oral GIP antagonists are in active development, aiming to capture a significant share of a large market. - Oncology pipeline and Seagen integration are expected to contribute significantly with multiple drugs advancing and delivering revenue growth. - Overall, operational revenue growth excluding COVID is guided at 9% to 11% for the year.

- Pfizer raised full-year 2024 total revenue guidance to $61 billion to $64 billion. - Operational revenue growth excluding COVID-19 products is expected at 9% to 11%. - COVID-19 product revenues projected at $10.5 billion ($5 billion for COMIRNATY and $5.5 billion for PAXLOVID). - Adjusted diluted earnings per share (EPS) guidance increased to $2.75 to $2.95. - EPS guidance includes an anticipated $0.40 dilution from the Seagen acquisition due to financing costs. - 2024 adjusted earnings per share benefitted by approximately $0.30 from favorable tax timing and audit settlements. - Pfizer maintains focus on reducing costs, expanding margins, and strategic capital deployment. - The company aims to drive enhanced operating leverage over time enabling consistent financial performance. - Continued strong performance, including oncology and new product launches, supports optimistic long-term growth and shareholder value creation.

- ABRYSVO (RSV vaccine) saw strong stocking efforts in Q3 to start the vaccination season, with supply held in fridges at retailers and partners. - Administration volumes during Q3 began in August but were lower compared to last year due to COVID vaccine timing and market dynamics; volumes expected to continue into Q4. - In international markets, ABRYSVO is gaining reimbursement in 45 countries, including U.K., Canada, Germany, Australia, and others, supporting future order growth and market penetration. - The U.S. market shows growth in diagnosis rates and patient starts, with Q3 new patient starts up 61% YoY and a 3% increase quarter-over-quarter. - Pediatric ABRYSVO uptake doubled in September compared to the last season, with shipments up 56% in early season weeks supporting strong order momentum. - The company is actively managing supply and stocking to meet demand while focusing on education and affordability to grow the orderbook sustainably into 2025.